Galmed Pharmaceuticals Analyst Ratings
Galmed Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/24/2023 | 247.83% | Maxim Group | → $4 | Upgrades | Hold → Buy |
| 08/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/08/2022 | -13.04% | Canaccord Genuity | $5 → $1 | Downgrades | Buy → Hold |
| 05/18/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 05/03/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 05/03/2022 | 334.78% | Raymond James | $14 → $5 | Maintains | Outperform |
| 05/17/2021 | 1726.09% | Canaccord Genuity | $20 → $21 | Maintains | Buy |
| 03/19/2021 | 2073.91% | HC Wainwright & Co. | $29 → $25 | Maintains | Buy |
| 01/08/2021 | 1378.26% | Raymond James | $20 → $17 | Maintains | Outperform |
| 11/25/2020 | 1639.13% | Canaccord Genuity | $25 → $20 | Maintains | Buy |
| 05/22/2020 | 595.65% | B. Riley Securities | $11 → $8 | Downgrades | Buy → Neutral |
| 05/15/2020 | 1639.13% | Raymond James | $25 → $20 | Maintains | Outperform |
| 03/13/2020 | 2073.91% | Stifel | $35 → $25 | Maintains | Buy |
| 03/13/2020 | 856.52% | B. Riley Securities | $28 → $11 | Maintains | Buy |
| 02/04/2020 | 1465.22% | Craig-Hallum | → $18 | Initiates Coverage On | → Buy |
| 01/30/2020 | 1117.39% | Cantor Fitzgerald | $59 → $14 | Assumes | → Overweight |
| 07/22/2019 | 2073.91% | Laidlaw & Co. | → $25 | Initiates Coverage On | → Buy |
| 12/12/2018 | 2334.78% | B. Riley Securities | → $28 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2023 年 7 月 24 日 | 247.83% | Maxim 集团 | → 4 美元 | 升级 | 持有 → 买入 |
| 08/08/2022 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 08/08/2022 | -13.04% | Canaccord Genu | 5 美元 → 1 美元 | 降级 | 买入 → 持有 |
| 05/18/2022 | — | 雷蒙德·詹姆 | 降级 | 跑赢大盘 → 市场表现 | |
| 05/03/2022 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
| 05/03/2022 | 334.78% | 雷蒙德·詹姆 | 14 美元 → 5 美元 | 维护 | 跑赢大盘 |
| 05/17/2021 | 1726.09% | Canaccord Genu | 20 美元 → 21 美元 | 维护 | 购买 |
| 03/19/2021 | 2073.91% | HC Wainwright & Co. | 29 美元 → 25 美元 | 维护 | 购买 |
| 01/08/2021 | 1378.26% | 雷蒙德·詹姆 | 20 美元 → 17 美元 | 维护 | 跑赢大盘 |
| 11/25/2020 | 1639.13% | Canaccord Genu | 25 美元 → 20 美元 | 维护 | 购买 |
| 05/22/2020 | 595.65% | B. 莱利证券 | 11 美元 → 8 美元 | 降级 | 买入 → 中性 |
| 05/15/2020 | 1639.13% | 雷蒙德·詹姆 | 25 美元 → 20 美元 | 维护 | 跑赢大盘 |
| 03/13/2020 | 2073.91% | Stifel | 35 美元 → 25 美元 | 维护 | 购买 |
| 03/13/2020 | 856.52% | B. 莱利证券 | 28 美元 → 11 美元 | 维护 | 购买 |
| 02/04/2020 | 1465.22% | Craig-Hallum | → 18 美元 | 启动覆盖开启 | → 购买 |
| 01/30/2020 | 1117.39% | 坎托·菲茨杰拉德 | 59 美元 → 14 美元 | 假设 | → 超重 |
| 07/22/2019 | 2073.91% | Laidlaw & Co. | → 25 美元 | 启动覆盖开启 | → 购买 |
| 2018 年 12 月 12 日 | 2334.78% | B. 莱利证券 | → 28 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Galmed Pharmaceuticals (GLMD)?
Galmed Pharmicals（GLMD）的目标价格是多少？
The latest price target for Galmed Pharmaceuticals (NASDAQ: GLMD) was reported by Maxim Group on July 24, 2023. The analyst firm set a price target for $4.00 expecting GLMD to rise to within 12 months (a possible 247.83% upside). 3 analyst firms have reported ratings in the last year.
Maxim集团于2023年7月24日公布了Galmed Pharmicals（纳斯达克股票代码：GLMD）的最新目标股价。这家分析公司将目标股价定为4.00美元，预计GLMD将在12个月内升至247.83％（可能上涨247.83％）。去年有3家分析公司公布了评级。
What is the most recent analyst rating for Galmed Pharmaceuticals (GLMD)?
分析师对Galmed Pharmicals（GLMD）的最新评级是多少？
The latest analyst rating for Galmed Pharmaceuticals (NASDAQ: GLMD) was provided by Maxim Group, and Galmed Pharmaceuticals upgraded their buy rating.
Galmed Pharmicals（纳斯达克股票代码：GLMD）的最新分析师评级由Maxim集团提供，Galmed Pharmicals上调了买入评级。
When is the next analyst rating going to be posted or updated for Galmed Pharmaceuticals (GLMD)?
Galmed Pharmicals（GLMD）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galmed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galmed Pharmaceuticals was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Galmed Pharmicals的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Galmed Pharmicals的最新评级是在2023年7月24日提交的，因此您应该预计下一个评级将在2024年7月24日左右公布。
Is the Analyst Rating Galmed Pharmaceuticals (GLMD) correct?
分析师对Galmed Pharmicals（GLMD）的评级正确吗？
While ratings are subjective and will change, the latest Galmed Pharmaceuticals (GLMD) rating was a upgraded with a price target of $0.00 to $4.00. The current price Galmed Pharmaceuticals (GLMD) is trading at is $1.15, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Galmed Pharmicals（GLMD）评级已上调，目标股价为0.00美元至4.00美元。Galmed Pharmicals（GLMD）目前的交易价格为1.15美元，在分析师的预测区间内。